Assessment of the Efficacy and Safety of Two Albendazole Regimens for the treatment of hypermicrofilaraemic loiasis in adult populations in Woleu-Ntem Province, Gabon: a Phase IIb single-blind randomised controlled trial

2025-05-25 infectious diseases Title + abstract only

Show abstract

BackgroundLoa (L.) loa hypermicrofilaraemia (>8,000 mf/mL) increases the risk of severe adverse events during mass ivermectin administration for onchocerciasis control. Albendazole has been proposed as a potential alternative for reducing microfilariaemia prior to treatment. Methodology and principal findingsThis prospective study was conducted in northern Gabon from November 2021 to April 2022. Individuals infected with L. loa were screened and allocated into three groups: two treatment arms r...